Cytomegalovirus Infection Market: Key Players and Production Information Analysis 2017 - 2025

Cytomegalovirus (CMV) infection is one of the common herpesvirus infection with different symptoms, which occurs in people of all ages across the globe. This viral infection is communicable and can easily spread through body fluids such as blood, urine, saliva, semen and breast milk. The infection can spread easily through saliva or urine and the people infected with the CMV may have the virus in their saliva or urine for months. The disease can be transmitted from pregnant women to the baby during the delivery. Blood transfusion and infected organ transplant is yet another mode of disease transmission.

Request for Table of Contents @ https://www.persistencemarketresearch.com/toc/17356

The infection can be diagnosed through serological testing methods such as Enzyme-linked immunoassay test.  Many of the cases of CMV goes undiagnosed in early stage of infection thus the awareness about the infection is most important factor. According to the Centers for Disease Control and Prevention (CDC), in U.S., each year around 150 infants are born with cytomegalovirus infections and few of them have long term health problems.  

The key factor responsible for growth of cytomegalovirus infection is increasing public awareness related to herpes virus infections which is fueling the diagnosis rate in North America and Europe. North America was observed as the largest market for cytomegalovirus infection treatment followed by Europe. Asia Pacific was anticipated to grow at a fastest CAGR during the forecast period. The key factors assisting the growth of Asia Pacific cytomegalovirus infection treatment market are the rising awareness associated with the rare diseases, developing healthcare infrastructure, high disposable income and government support for novel treatment against rare genetic diseases.

Based on product type, the market is segmented into Cidofovir, Foscarnet,  Valganciclovir, and Ganciclovir. These are few of the most prescriobed medication for the treatment of cytomegalovirus. Similarly, based on distribution channel, the market is segmented into, hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies are expected to hold maximum share in the market due to the easy availability of medication and increasing prescription patterns for the treatment of CMV.

Region wise, the global cytomegalovirus infection market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, and Middle East and Africa. The growth of CMV virus is attributed to the increasing awareness regarding the herpes virus and increasing diagnosis rate in developed region such as North America and Europe.  Similarly, the government initiatives for the awareness regarding rate disease, growing healthcare expenditure and escalating disposable income are few of the factors responsible the market growth in Asia-Pacific.

Request to View Sample of Research Report @ https://www.persistencemarketresearch.com/samples/17356

The key players in the market are F. Hoffmann-La Roche, GlaxoSmithKline plc, Vical, Inc., AiCuris Anti-infective Cures GmbH, ViroPharma, Chimerix, Inc., and others.

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States,

Telephone - +1-646-568-7751

USA – Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

This release was published on openPR.